Regenxbio RGNX Deferred Equity Offering Costs Reclassified

Deferred Equity Offering Costs Reclassified at other companies

Solana CompanyHSDT

$8K-93.9%

Mineralys Therapeutics, Inc.MLYS

$200K-33.3%

Schering-PloughSGP

$0—

DeFi Development Corp.DFDV

$3.36M+2,861%

Alpha CognitionACOG

$223.1K—

BeneficientBENF

$0-100%

FAQ

What is Regenxbio's deferred equity offering costs reclassified?

Regenxbio (RGNX) reported deferred equity offering costs reclassified of $124.75K in Q4 2025.

How has Regenxbio's deferred equity offering costs reclassified changed year-over-year?

Regenxbio's deferred equity offering costs reclassified decreased by 20.5% year-over-year, from $157K to $124.75K.

What does deferred equity offering costs reclassified mean?

This metric represents the reclassification of previously deferred equity issuance costs, typically occurring when the associated equity offering is completed or abandoned. It reflects the accounting adjustment that moves these costs from a deferred asset or liability status to a reduction of equity proceeds or an expense. This is essential for understanding the net proceeds realized from capital market activities.